Share
AACR Annual Meeting 2023
Orange County Convention Center, Orlando, Florida
April 14, 2023 - April 19, 2023The AACR Annual Meeting highlighted the best cancer science and medicine from institutions all over the world. Attendees were invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research. Check out our poster and presentation from the event and explore our products and resources below to see how we can support cancer diagnostics and drug development.
Did you miss us at booth #1633 and would like to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
Check Out Our Exhibitor Spotlight Theater
Cell-based Models for the Discovery and Development of Cancer Therapeutics
Check out our presentation to learn about our portfolio of 2-D and 3-D models from the Human Cancer Models Initiative (HCMI) consortium and our new immuno-oncology reporter models for accelerating your oncology drug discovery and development.
Presenters: Utsav Sharma, PhD, Product Manager, Oncology, ATCC; Hyeyoun Chang, PhD, Scientist, ATCC; James Clinton, PhD, Lead Scientist, ATCC
Date: April 18, 2023
Time: 12:30 PM – 1:30 PM
Location: Spotlight Theater D
Watch Our Poster Session
Immune Checkpoint Reporter Cell Lines Based on the Protein Profiling of ATCC Cell Lines for Cancer Immunotherapy Drug Screening
Watch our poster session to learn about the development of immune checkpoint reporter cell lines and their application in immunotherapy drug screening.
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: April 19, 2023
Time: 9:00 AM – 12:30 PM
Location: Section 38
Poster Board Number: 15
Abstract Presentation Number: 6643
Human Cancer Models Initiative
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.
ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Find next-generation modelsResources for cancer diagnostics and drug development
Luciferase-labeled cell lines
ATCC is bridging the gap between the in vitro and the in vivo by offering luciferase-labeled cell lines for biological mechanism studies and drug development; these advanced models provide a relatively simple, robust, and highly sensitive means to measure biological processes and to assess drug efficacy in live animal models through bioluminescence imaging.
Get started
Next-generation cancer models
ATCC is offering scientists a wide variety of next-generation patient-derived in vitro cancer models, including organoids, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These advanced models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Discover how
EMT reporter cells
Epithelial-mesenchymal transition (EMT) and its reverse, MET, can play critical roles in promoting metastasis and invasion and contribute to drug resistance in carcinoma. ATCC used CRISPR gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.
Enhance your research
THP-1 reporter cells
ATCC offers luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. These advanced models provide a robust and highly sensitive means to measure immune activation through in vitro bioluminescence.
Order THP-1 reporter cell lines
Cancer panels
ATCC offers a wide variety of cancer cell lines for use in research related to cancer genetics, early detection methods, and effective treatment of disease. Panels of these cell lines offer researchers the value of several lines for comprehensive studies. Explore our panels by tissue type, genetic mutation, or molecular signature.
Order cancer panels
Matched normal and cancer cells
Cancer research starts out with the investigation of the biological differences between normal, healthy cells and cancerous cells. That's why ATCC offers authenticated tumor-derived cell lines matched to normal cells from the same donor to provide you with a valuable starting point for your cancer studies.
Get the cells
hTERT-immortalized cells
Human telomerase reverse transcriptase (hTERT)–immortalized cells represent a breakthrough in cell biology research that combines the in vivo nature of primary cells with the traditional cell line's ability to survive continuously in vitro. Our collection encompasses a variety of cell types derived from human tissue.
Browse hTERT-immortalized cells
Isogenic cells
Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for elucidating molecular pathways of cancer progression.
Explore isogenic cells
Primary cells
Human primary cells more closely mimic the physiological state of cells in vivo and generate more relevant data representing living systems. ATCC Primary Cell Solutions consist of quality cells, reagents matched and optimized to work with each ATCC primary cell type, and trustworthy tips and techniques.
order primary cells
Download a PDF of our literature
Immuno-oncology Tools
ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.
More
CAR-T Target Luciferase Reporter Cells
ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.
More
Cell Lines by Gene Mutation
This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.
More
Genetic Alteration Cell Panel
A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.
More
Isogenic Cell Lines
With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.
More
THP-1 Reporter Cells
ATCC introduced luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. The THP-1 LUC2 cell lines provide a means to confidently measure immune modulation for all your drug discovery and development efforts.
More
ATCC Tumor Cell Panels by Gene Mutations and Tissue Origin
The value of tumor cell lines, as research models and drug discovery tools, is greatly enhanced when there is an understanding of the underlying genetic abnormalities that drive their phenotype. ATCC has taken the first step for your research by annotating our tumor cell lines with gene mutation data from the Sanger Institute COSMIC database, and additional in-house testing.
More
Tumor/Normal Matched Cell Line Pairs
Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.
More
Contact us today
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.
